Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | $16.29 | -$8.16 | -33.37% | 16M | $2.4B | $10.42$138.81 |
| ICHR | Ichor | $16.37 | -$6.55 | -28.58% | 1.7M | $786.8M | $13.12$36.48 |
| JELD | Jeld-wen | $3.01 | -$1.19 | -28.33% | 5.3M | $358.7M | $2.31$11.66 |
| NOMA | Nomadar | $8.35 | -$3.15 | -27.39% | 54K | - | $2.00$57.70 |
| FLYE | Fly-E Group | $7.39 | -$2.61 | -26.10% | 70.7K | $189.0M | $7.23$166.00 |
| ESLA | Estrella Immunopharma | $2.27 | -$0.79 | -25.74% | 686.9K | $113.1M | $0.70$3.15 |
| SLDB | Solid Biosciences | $3.97 | -$1.23 | -23.72% | 1.4M | $404.9M | $2.41$7.37 |
| CJET | Chijet Motor | $2.94 | -$0.89 | -23.23% | 215.4K | $350.4M | $2.77$299.00 |
| MIMI | Mint Incorporation | $3.35 | -$0.97 | -22.45% | 2M | $108.1M | $3.20$13.69 |
| FORD | Forward Industries | $10.92 | -$3.06 | -21.89% | 1.7M | $1.2B | $3.32$46.00 |
Related Articles
Featured Article
Is This Stock a Buy After Soaring by 20% in 1 Day?
Prosper Junior Bakiny|Jul 24, 2025
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi|Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski|Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|Jul 3, 2024
Let's look beyond the biotech's performance this year.
1 Top Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|May 1, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Alex Carchidi|Mar 13, 2024
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Alex Carchidi|Mar 4, 2024
The upcoming regulatory decision on its latest drug could be big.
Is It Too Late to Buy Sarepta Therapeutics Stock?
Prosper Junior Bakiny|Feb 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
2 Magnificent Growth Stocks to Buy With $500
Prosper Junior Bakiny|Feb 15, 2024
No need to break the bank to invest in promising stocks.
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Alex Carchidi|Feb 11, 2024
Bad news for one player does not always equal good news for another.
